Jennifer R. Brown is one of the specialists who best knows chronic lymphocytic leukemia (CLL), the most common form of leukemia among the adult population in the Western world. This is attested to by the more than 150 articles published by him and his contribution to the clinical development of treatments for this blood cancer. The director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute chairs the congress of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), a world reference in the study of LLC.
Brown claims a scientific mentality in medicine. After completing a bachelor’s and master’s degree simultaneously in Molecular Biophysics and Biochemistry at Yale, he entered Harvard Medical School, where he earned a doctorate in Molecular Genetics; Later, he did his residency in Internal Medicine at Massachusetts General Hospital and specialized in Hematology and Medical Oncology at Dana-Farber in Boston, where he has focused on the treatment of chronic lymphocytic leukemia (CLL). The arrival of new medications is making the prognosis for this oncohematological disease among the most promising.